All In Biotech

Drug Trial Radar · NCT07830667

A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat

A Phase 1/2 Study of CBX-12 in Pediatric Patients With Relapsed or Refractory Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

79

Planned (sponsor's estimate)

Start

May 7, 2027

Primary completion

Jun 30, 2033

Study completion Jun 30, 2033

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial tests the safety, best dose, and effectiveness of CBX-12 in the treatment of pediatric patients (ages 12 months to 30 years) with rhabdomyosarcoma, Ewing sarcoma, or other extracranial solid tumors that have come back after a period of improvement (relapsed) or that do not respond to treatment (refractory). CBX-12 is a conjugate drug made of a peptide linked to a drug called exatecan. Upon administration, the peptide portion of CBX-12 gets inserted into the membrane of tumor cells and then exatecan is released into the tumor cells. Exatecan inhibits deoxyribonucleic acid replication in tumors cells, leading to tumor cell death. CBX-12 may be a safe and effective treatment option for pediatric patients with relapsed or refractory rhabdomyosarcoma, Ewing sarcoma, or other solid tumors.

Conditions

  • Recurrent Childhood Ewing Sarcoma
  • Recurrent Childhood Malignant Solid Neoplasm
  • Recurrent Childhood Rhabdomyosarcoma
  • Recurrent Ewing Sarcoma
  • Recurrent Extracranial Malignant Solid Neoplasm
  • Recurrent Rhabdomyosarcoma
  • Refractory Childhood Ewing Sarcoma
  • Refractory Childhood Malignant Solid Neoplasm
  • Refractory Childhood Rhabdomyosarcoma
  • Refractory Ewing Sarcoma
  • Refractory Extracranial Malignant Solid Neoplasm
  • Refractory Rhabdomyosarcoma

Interventions

  • Archive Sample RetrievalProcedure

    Ancillary studies

  • Biospecimen CollectionProcedure

    Undergo collection of bone marrow and blood samples

  • pH Low Insertion Peptide-exatecan Conjugate CBX-12Drug

    Given IV

  • Radiologic Imaging ProcedureProcedure

    Undergo radiologic imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
  2. Recommended phase 2 dose (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
  3. Incidence of adverse events (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
  4. Pharmacokinetics (part A phase 1 dose escalation)Time frame: During cycle 1 of part A (dose escalation phase; cycle length = 21 days)
  5. Objective response rate (part B phase 2 dose expansion)Time frame: Up to 60 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.